The REVOLUTION study, Diabetes Epidemiology and Management (2024) Efficacy of semaglutide in a subcutaneous and oral formulation, Frontiers in Endocrinology (2021) Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial, Nature Medicine (2022) Real-world use of oral versus subcutaneous semaglutide in a cohort of Type 2 diabetic patients: which option to which patient?, Journal of Endocrinological Investigation (2024) FDAs concerns with unapproved GLP-1 drugs used for weight loss, FDA.gov (2024) Dietary supplements for weight loss, National Institutes of Health Evaluation of efficacy and safety of orlistat in obese patients, Indian Journal of Endocrinology and Metabolism (2011) A systematic review of dietary supplements and alternative therapies for weight loss, Obesity (2021) Are weight loss supplements safe?, Poison Control Tainted weight loss products, FDA.gov Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice
Therapeutic peptides generally work by binding to cellular surfaces and triggering effects within the cells
Dehydration and acute kidney injury risk is elevated with persistent gastrointestinal losses, particularly in older adults or those taking diuretics or RAAS-blocking medicines
If approved, you receive a REMPE electronic prescription (PDF file) in your Hi-Doctor account and by email within 24 hours
The study examined genetic variants in the GLP1R gene across diverse populations, including 408,774 white British individuals, 50,314 white Europeans, 7,667 South Asians, 10,437 individuals of multiple ancestries, and 7,641 African-Caribbeans
